FDA Approves DIFLUPREDNATE — Alembic Pharmaceuticals Inc.

# FDA Approves Generic Difluprednate Ophthalmic from Alembic Pharmaceuticals The FDA has approved Alembic Pharmaceuticals' generic difluprednate ophthalmic formulation, expanding treatment options in the corticosteroid eye drop market and introducing potential cost savings for patients managing inflammatory eye conditions. The approval is expected to increase competition in this therapeutic segment, potentially pressuring pricing for the branded alternative.